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Study objective: Acute urticaria is a frequent presentation in emergency departments (EDs), urgent care centers, and other
clinical arenas. Treatment options are limited if diphenhydramine is the only intravenous antihistamine offered because of its
short duration of action and well-known adverse effects. We evaluate cetirizine injection, the first second-generation injectable
antihistamine, for acute urticaria in this multicenter, randomized, noninferiority, phase 3 clinical trial.
Methods: Adult patients presenting to EDs and urgent care centers with acute urticaria requiring an intravenous antihistamine
were randomized to either intravenous cetirizine 10 mg or intravenous diphenhydramine 50 mg. The primary endpoint was the 2-
hour pruritus score change from baseline, with time spent in treatment center and rate of return to treatment centers as key
secondary endpoints. Frequency of sedation and anticholinergic adverse effects were also recorded.
Results: Among 262 enrolled patients, the 2-hour pruritus score change from baseline for intravenous cetirizine was statistically
noninferior to that for intravenous diphenhydramine (–1.6 versus –1.5; 95% confidence interval –0.1 to 0.3), and in favor of
cetirizine. Treatment differences also favored cetirizine for mean time spent in treatment center (1.7 versus 2.1 hours; P¼.005),
return to treatment center (5.5% versus 14.1%; P¼.02), lower change from baseline sedation score at 2 hours (0.1 versus 0.5;
P¼.03), and adverse event rate (3.9% versus 13.3%).
Conclusion: Intravenous cetirizine is an effective alternative to intravenous diphenhydramine for treating acute urticaria, with
benefits of less sedation, fewer adverse events, shorter time spent in treatment center, and lower rates of revisit to treatment
center. [Ann Emerg Med. 2020;-:1-12.]
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INTRODUCTION
Background
Acute urticaria is frequently observed in emergency
departments (EDs), urgent care centers, inpatient hospital
units, and other clinical arenas throughout the health care
system (oncology, dermatology, rheumatology, radiation,
and general medicine clinics). Acute urticaria is a vascular
skin reaction marked by transient, erythematous, intensely
pruritic raised wheals or similar rash with or without
angioedema.1 It characteristically appears quickly, resolves
during hours, and may repeatedly recur for up to 6 weeks.2
Nearly 450,000 visits are made annually to EDs for
urticaria, according to the 2016 US National Hospital
Ambulatory Medical Care Survey.3 Acute urticaria typically
responds to pharmacotherapy, with antihistamines being
the first-line treatment.4 The parenteral route of
administration is often preferred to provide rapid onset of
action.1
Importance
Until recently, the first-generation short-acting
antihistamine diphenhydramine was the only antihistamine
available for intravenous administration. Its adverse event
profile includes sedation and other anticholinergic adverse
effects (eg, urinary retention, constipation, dry mouth,
other central nervous system impairment)5 that may
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Editor’s Capsule Summary
What is already known on this topic
Parenteral diphenhydramine is a long-standing but
sedating option for treating acute urticaria.
What question this study addressed
How does intravenous cetirizine 10 mg, a newer
antihistamine, compare with intravenous
diphenhydramine 50 mg in acute treatment of acute
urticaria?
What this study adds to our knowledge
In a 262-subject, randomized, blinded trial in either
an emergency department or urgent care setting,
cetirizine was noninferior to diphenhydramine in
relieving itch at 2 hours, with shorter care intervals,
decreased sedation, and lower adverse events rates.
How this is relevant to clinical practice
This agent is an option in the narrow group of
urticaria patients needing parenteral therapy.
complicate clinical management and delay ED or urgent
care discharge.1,4,6-9
Hydroxyzine, another first-generation antihistamine, is
contraindicated for intravenous use. It can be used only as
an intramuscular injection; additionally, hydroxyzine
injection is not approved by the Food and Drug
Administration for the treatment of allergic reaction or
acute urticaria.10 It has an adverse effect profile similar to
that of diphenhydramine, including sedation and cognitive
impairment.
First-generation antihistamines are known to cause
significant driving impairment comparable to or greater
than that of alcohol intoxication (blood alcohol level of
0.1%), leading to recommendations that patients not drive
after treatment.11-13 The second-generation antihistamines
(including cetirizine, loratadine, and fexofenadine) are
associated with a decreased rate of sedation, a 24-hour
duration of action, minimal anticholinergic effects, as well
as lower rates of other adverse effects associated with first-
generation antihistamines.1,6,9,14 Because it is not feasible
to conduct a placebo-controlled clinical trial with patients
with an acute condition, regulatory agencies and
investigator review boards suggest conducting a
noninferiority clinical trial. In a phase 2 clinical study
(Efficacy Trials for the Treatment of Acute Urticaria 2),
intravenous cetirizine achieved acute urticaria symptom
score reductions similar to those of intravenous
diphenhydramine while allowing less time spent in
treatment centers because of decreased sedation levels.
Intravenous cetirizine also resulted in lower symptom
recurrence rates.
Goals of This Investigation
Whereas oral cetirizine is indicated for chronic urticaria,
intravenous cetirizine is indicated for the treatment of acute
urticaria associated with acute allergic reactions. These are
different indications for different conditions, although with
similarities involving histamine release. This phase 3
multicenter randomized trial (ETTAU-03) evaluated the
efficacy and other treatment outcomes of intravenous
cetirizine versus intravenous diphenhydramine in patients
with acute urticaria. The primary objective was to establish
the noninferiority of intravenous cetirizine relative to
intravenous diphenhydramine in reducing the patient-
reported pruritus severity score at 2 hours after treatment of
acute urticaria. The key secondary efficacy and clinical
measures of this study were the time spent at the treating
facility and need to return to a treatment center, with a
number of other assessed outcomes that included
physician-rated extent of urticaria and erythema scores,
pruritus treatment success rates, effective treatment rates,
rescue medication use, sedation, and adverse events.
MATERIALS AND METHODS
Study Design and Setting
This was a multicenter, double-blind, randomized,
phase 3 clinical trial with a parallel-group, active-controlled,
noninferiority design. The study was conducted at 19 sites
in the United States and Canada. Patients were considered
for enrollment if they presented with acute urticaria to EDs
or urgent care centers. Relevant institutional review boards
at each participating site granted approval for the conduct
of this trial. Written informed consent was obtained from
each patient through an approved standard process.
Selection of Participants
Inclusion criteria for the trial were patients aged 18 years
or older who required an antihistamine to relieve symptoms
of acute urticaria (based on the clinical judgment of the
investigator), with a patient-rated pruritus severity score
greater than or equal to 1, and willing and able to give
informed consent. Patients who, according to investigator
assessment, had acute urticaria caused by a reaction to a
current medication (eg, antibiotics, nonsteroidal anti-
inflammatory drugs) but who could stop the medication
after presenting to the site were eligible. Patients who
presented with acute urticaria together with angioedema or
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anaphylaxis, provided that urticaria was still present after
initial treatment and alleviation of anaphylaxis symptoms,
were qualified to be enrolled.
Patients were excluded if they had anaphylaxis before the
acute anaphylactic symptoms were treated. Other key
exclusion criteria were contraindication, known allergy, or
suspected intolerability to study medication, receipt of an
H1 or H2 antagonist or doxepin in the previous 2 hours,
corticosteroids (any route) in the previous 4 hours,
epinephrine in the previous 20 minutes, and concomitant
use of p-glycoprotein inhibitors (including amiodarone,
clarithromycin, erythromycin, ketoconazole, quinidine,
and saquinavir).
Interventions
Eligible patients were randomized in a 1:1 ratio to
receive a single dose of cetirizine 10 mg or
diphenhydramine 50 mg, each administered as a single 1.0-
mL injection by an approximately 2-minute intravenous
push.
Additional medications (epinephrine, corticosteroids,
etc) were allowed as rescue drugs if deemed necessary by the
investigator or designee. However, if the patient was
without medical complication, all efforts were made to have
him or her complete at least the 1-hour assessment before
administration of any rescue medication. If patients
required rescue medication shortly after study drug
administration (eg, within approximately 10 to 15
minutes), this indicated that they may have had
anaphylaxis, and they were therefore immediately
withdrawn from the study.
Treatment drugs intravenous cetirizine and intravenous
diphenhydramine were visually identical clear aqueous
solutions in 2-mL amber vials containing 1 mL of
medication. Treatment drugs were prerandomized and
preblinded by the sponsor’s contract research organization,
according to a centralized randomization schedule (generating
a randomization list in blocks of 4), before being delivered to
each investigational site. A treatment vial, consisting of one
vial of either intravenous cetirizine or intravenous
diphenhydramine, was packaged and labeled by the
randomization number, with a blinded label to conceal the
product name. To further maintain blinding, a staff member
who was not involved in patient management or outcome
assessment was responsible for drawing up the randomized
medication into a syringe for administration. The health care
professional involved in patient management and outcome
assessment was completely blinded.
Treatment group assignment was denoted by sequential
numbers within a site randomization list, which was kept
secured by the contract research organization until the
study blind was broken. To preserve the blinding of the
study at the investigational site, site personnel did not have
access to the randomization code and treatment
assignments before database lock. Study blinding was to be
broken only if the identity of the study drug was considered
vital for the clinical management of the patient.
Methods of Measurement
Clinical efficacy measures included the patient-rated
pruritus severity score (primary outcome measure; see later
text) and sedation score; the physician-rated extent of
urticaria/erythema score, assessed at baseline and 1 and 2
hours posttreatment; and time to discharge. The patient-
rated pruritus score was adapted from a previously validated
scoring scale for chronic urticaria (to our knowledge, acute
urticaria had never been studied in a pivotal clinical trial
before the study of cetirizine reported here), with a severity
score of 0 to 3 (0¼none, 1¼mild, 2¼moderate, and
3¼severe) in response to the question, How severely are
your hives itching at the moment?15 The investigators also
provided extent of urticaria/erythema scores (percentage of
body area affected and the intensity of redness, using a burn
wound assessment chart) on a 0-to-3 scale, and an
assessment of whether a patient was “effectively treated.”
Use of rescue medications (epinephrine, bronchodilators,
corticosteroids, etc) and additional pharmacologic agents
(including the reason for use, symptom recurrence or
additional symptom occurrence, and the ability to return to
normal activity) was assessed with a questionnaire given at
follow-up telephone calls 24 hours after discharge, 48 hours
after discharge, or both. The patient-rated sedation score
was recorded by research staff according to a severity score
of 0 to 3 (0¼none [not drowsy at all], 1¼mild [slightly
drowsy], 2¼moderate [quite drowsy], and 3¼severe
[extremely drowsy]) in response to the question, How
drowsy do you feel at the moment? The time spent at the
treatment center (time from treatment administration to
readiness for discharge) and the need to return to the
treatment center after study discharge (ie, a second visit
after discharge) were also assessed, with the latter
determined by patient follow-up telephone calls. Safety was
evaluated by monitoring vital signs and adverse events (at
site arrival, baseline, 1 and 2 hours postadministration, and
discharge), with adverse events subsequently recorded 24
hours and 48 hours after discharge, and for up to 28 days
after treatment through patient self-reporting.
Outcome Measures
The primary efficacy endpoint was the change in
patient-rated pruritus score from baseline to 2 hours after
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treatment administration. Two key secondary efficacy
outcomes were percentage of patients who returned to any
ED or clinic, and the time spent at the treatment center
(time from treatment administration to discharge
readiness). Additional secondary outcomes reported
included change from baseline to 2 hours in physician-rated
extent of urticaria/erythema scores; percentage of patients
needing rescue medication, pruritus treatment success,
effectively treated, returning to normal activity, and
symptom recurrence after discharge; patient-reported
sedation scores; and adverse event rates. Pruritus treatment
success was a patient-reported outcome defined as a
reduction in pruritus severity score at 2 hours of at least 1
unit compared with baseline. This contrasted with the
measure of effectively treated patients, a physician-reported
outcome based on the investigator’s opinion of yes or no.
Primary Data Analysis
A sample size of 127 patients per arm (total N¼254)
was needed to provide 90% statistical power to determine
whether intravenous cetirizine would be noninferior to
intravenous diphenhydramine, as calculated from the
previous ETTAU-02 study. The sample size was
established according to the assumption of –0.5 as the
noninferiority margin for the primary outcome measure of
pruritis score. Agreement with the regulatory agency on
–0.5 as the noninferiority margin was based on sponsor’s
phase 2 clinical results from the intravenous cetirizine
versus intravenous diphenhydramine study, which showed
that the 95% confidence interval (CI) around the change
from baseline after 2 hours of treatment with
diphenhydramine spanned the width of 0.5 units. The
null hypothesis was that intravenous cetirizine was inferior
to intravenous diphenhydramine if the treatment difference
in the change from baseline in patient-rated pruritus score
at 2 hours had a 95% CI that included –0.5.
The primary analysis was performed for the intention-
to-treat population (all randomized patients who were
given a subject identification number with intention to
treat with blinded study drug) with the last observation
carried forward imputation method used to impute 2-hour
scores if patients were discharged before this assessment.
The point estimate of treatment differences of the change
from baseline of 2-hour patient-rated pruritus severity score
and the 95% CIs were to be calculated with a 2-sided t test
from a generalized linear mixed-effects model to adjust for
any heterogeneity of treatment variance, to adjust for
imbalance in numbers of patients in each treatment, and to
adequately model the resulting interval outcome. The
model initially consisted of the change from baseline at 2
hours as the dependent variable and site, treatment, and
sitetreatment as fixed effects. It was observed in this a
priori analysis that site effects contributed greatly to the
variability of the outcome; however, there were no
sitetreatment interactions. In addition, baseline pruritus
scores were found to be a significant covariate. Because the
number of sites was relatively large for a fixed-effect model
with site and because sitetreatment interactions were not
significant, an additional analysis was performed on the
primary analysis intention-to-treat population, using a
model that allowed site to be a random factor and included
baseline pruritus as a covariate. Results of the model,
considered to be a better fit than the a priori model
according to goodness-of-fit statistics, are reported here.
The 2 key secondary efficacy outcomes were adjusted for
multiplicity to minimize type I error; no adjustments for
multiplicity were made for the other secondary endpoints.
Safety analyses included patients who received blinded
study drug, regardless of whether they completed all
assessments, withdrew, or were discontinued by the
investigator. Evaluation of the primary endpoint based on
age was performed as a post hoc analysis. All statistical
analyses and summaries were performed with SAS (version
9.4; SAS Institute, Inc., Cary, NC).
RESULTS
Characteristics of Study Subjects
Of 268 screened patients, a total of 262 eligible ones
were randomized to intravenous diphenhydramine
(n¼135) or intravenous cetirizine (n¼127) at 19 study
centers in North America (Figure 1) between March 2,
2017, and April 14, 2018, for whom baseline demographic
and disease characteristics are summarized in Table 1. The
baseline characteristics between groups were comparable.
Of the 19 sites, 17 were EDs and 2 were urgent care
centers. Of the 262 patients enrolled, 222 (84.7%)
presented to hospital EDs and 40 (15.3%) presented to
urgent care centers. No patients presenting with
anaphylaxis participated in the trial.
All randomized patients were included in both the
intention-to-treat efficacy and safety populations
(Figure 1).
The primary efficacy data are presented in Table 2 and
Figure 2. With a mean change from baseline in patient-
rated pruritus severity score of –1.6 (SD 0.9) for
intravenous-cetirizine-treated patients and –1.5 (SD 1.0)
for intravenous-diphenhydramine-treated patients, the least
squares estimated treatment difference was 0.1 (95% CI
–0.1 to 0.3; P¼.35). Because the lower bound of the 95%
CI for the treatment difference did not include –0.5,
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effectiveness of intravenous cetirizine was determined to be
statistically noninferior to that of intravenous
diphenhydramine. There were also no treatment differences
for the primary efficacy outcome based on patients’ age
(<65 and 65 years) (Table 3).
Statistically significant differences favoring intravenous
cetirizine over intravenous diphenhydramine were observed
with respect to the key secondary outcomes as shown in
Table 4: both the time spent in the treating facility and the
proportion of patients needing to return to a treatment
center within 24 hours and 48 hours of patient discharge,
captured by postdischarge patient follow-up.
Other secondary efficacy measures are also shown in
Table 4. Mean changes from baseline to 2-hour physician-
rated urticaria/erythema scores were similar between
intravenous cetirizine and intravenous diphenhydramine
(–0.6 [SD 0.6] versus -0.5 [SD 0.6]).
The number of patients whose pruritus was successfully
treated was similar for both treatment groups. However,
the number of “effectively treated” patients according to
physician assessment was higher in the intravenous
cetirizine treatment group (P¼.02). There were fewer
patients in the intravenous cetirizine group who required
rescue drug usage compared with the intravenous
diphenhydramine group (P¼.016). The most common
rescue medication was corticosteroids in both groups
(intravenous cetirizine, n¼15 [12%], versus intravenous
diphenhydramine, n¼31 [23%]), with infrequent
epinephrine administration (intravenous cetirizine, n¼1
[1%], versus intravenous diphenhydramine, n¼3 [2%]).
After treatment, patient-rated sedation scores increased
in both treatment groups during the first hour (Figure 3).
Mean sedation score increases from baseline in the
intravenous cetirizine group were significantly smaller than
Assessed for eligibility (n=268)
Excluded (n 6)
No IV access (n=3)
Other reasons:
Symptoms resolved prior to treatment (n=1)
Screen failure (n=1)
Discontinued study prior to study drug 
exposure (n=1)
Analyzed (n=135)
Intention-to-treat population (n=135)
Safety population (n=135)
Per protocol population (n=130)
Lost to follow-up (n=3)
Wrong phone number; missing both 
24h and 48h follow-up data (n=1) 
No answer to ≥5 phone call attempts; 
missing both 24h and 48h follow-up
data (n=2)
Allocated to IV diphenhydramine (n=135)
Received allocated intervention (n=135)
Lost to follow-up (n=4)
Eloped; missing discharge info (n=1)
No answer to ≥5 phone call attempts; 
missing both 24h and 48h follow-up
data (n=3)
Allocated to IV cetirizine (n=127)
Received allocated intervention (n=127)
Analyzed (n=127)
Intention-to-treat population (n=127)
Safety population (n=127)
Per protocol population (n=121)
Allocation
Follow-Up
Randomized (n=262)
Enrollment
Analysis
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of study enrollment. The intention-to-treat (ITT)
population included any patient who was randomized and given a subject identification number with intention to treat with one of
the blinded study drugs. The safety population included any patients in the intention-to-treat population who actually received a
blinded study drug, regardless of whether they completed all assessments, withdrew, or were discontinued by the investigator. The
per-protocol population included patients in the safety population who completed all necessary assessments without any incidence
that would potentially affect the ability to objectively assess treatment response (discontinuation, protocol deviation, etc).
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those observed in the intravenous diphenhydramine group
at 1-hour assessment (0.2 [SD 0.8] versus 0.7 [SD 0.9];
P¼.003), 2-hour assessment (0.1 [SD 0.8] versus 0.5 [SD
0.9]; P¼.03), and discharge (0.1 [SD 0.8] versus 0.5 [SD
0.9]; P¼.04). The mean sedation score increases were also
smaller in the intravenous cetirizine group versus the
intravenous diphenhydramine group in patients aged 65
years or older at 1-hour assessment (0.0 [SD 0.5] versus 0.7
[SD 0.9]), 2-hour assessment (0.0 [SD 0.7] versus 0.3 [SD
0.9]), and discharge (0.0 [SD 0.7] versus 0.4 [SD 0.7]).
Overall, 31 adverse events were reported, 24 in the
intravenous diphenhydramine group and 7 in the
intravenous cetirizine group. Twenty-three patients
(8.8%) experienced at least 1 adverse event, including
18 (13.3%) intravenous-diphenhydramine-treated
patients and 5 (3.9%) intravenous-cetirizine-treated
patients. Dizziness and nausea were the most common
adverse events, all occurring in the intravenous
diphenhydramine group (dizziness: n¼6 [4.4%];
nausea: n¼4 [3.0%]) (Table 5). None of the adverse
Table 1. Characteristics of patients receiving intravenous diphenhydramine or intravenous cetirizine for treatment of acute urticaria.
Characteristic IV Diphenhydramine 50 mg (n[135) IV Cetirizine 10 mg (n[127)
Age, y
Mean (SD) 39.2 (16.0) 39.0 (16.3)
Median 37.0 36.0
Range 18–87 18–92
Sex, No. (%)
Women 88 (65) 77 (61)
Men 47 (35) 50 (39)
Race, No. (%)
White 62 (46) 64 (50)
Black 44 (33) 41 (32)
Asian 5 (4) 4 (3)
Other 3 (2) 2 (2)
Native Hawaiian or other Pacific Islander 0 1 (1)
Ethnicity, No (%)
white, Hispanic or Latino 0 1 (1)
Nonwhite, Hispanic or Latino 21 (16) 14 (11)
Presenting complaint(s), No. (%)
Urticaria only 118 (87) 110 (87)
Urticariaþangioedema 16 (12) 16 (12)
Angioedema only 1 (1) 1 (1)
Known allergies, No. (%)
None 102 (76) 100 (79)
Antibiotic drugs* 13 (10) 10 (8)
Other medications† 9 (7) 5 (4)
Food‡ 4 (3) 9 (7)
Other§ 9 (7) 3 (2)
IV, Intravenous.
Intention-to-treat population. Percentages may add up to more than 100% because of rounding or multiple known allergies in a single patient.
*IV diphenhydramine arm: amoxicillin (3), sulfa (2), vancomycin (2), sulfa (1), cefprozil (1), nitrofurantoin (1), levofloxacin (1), neomycin/polymyxin/hydrocortisone otic solution (1),
and unspecified antibiotic for tooth infection (1). IV cetirizine arm: sulfa (4), amoxicillin (2), sulfa/penicillin (1), fluconazole (1), vancomycin (1), and daptomycin (1).
†IV diphenhydramine arm: naproxen (1), aspirin (1), liraglutide (1), Tylenol Cold and Flu (1), fentanyl (1), cocaine/crack (1), escitalopram (1), amitriptyline (1), iron sucrose
supplement (1). IV cetirizine arm: lamotrigine (1), prednisone (1), meloxicam (1), naproxen (1), and loperamide (1).
‡IV diphenhydramine arm: dairy/eggs/peanuts (1), nuts/seafood (1), shrimp (1), and blueberry pancakes (1). IV cetirizine arm: peanuts (2), shellfish (2), shrimp (1), fish/seafood
(1), milk/inflammatory food (1), kiwi (1), and white bread (1).
§IV diphenhydramine arm: IV contrast (3), hair dye (1), lotion (1), perfume (1), new razor product (1), unspecified plant at home (1), and poison ivy (1). IV cetirizine arm: IV contrast
(1), bee stings (1), and hair dye (1).
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events in the intravenous cetirizine group occurred in
greater than one patient.
There were 10 patients who developed adverse
events related to study treatment. Nine patients were
receiving intravenous diphenhydramine and one was
receiving intravenous cetirizine. Patients reported
dizziness (n¼5) and nausea (n¼3) as the most
common intravenous-diphenhydramine-related adverse
events. Regarding intravenous-cetirizine-related
adverse events, one patient developed a combination
of dysgeusia, paresthesia, and sensation of warmth.
No overall differences in safety were observed in
patients aged 65 years or older versus younger
patients.
Figure 2. Patient-rated pruritus score and change by visit. Intention-to-treat population. The adjusted treatment difference between
intravenous diphenhydramine versus intravenous cetirizine was 0.1 (P¼.65) at baseline, –0.1 (P¼.76) at 1 hour, 0.1 (P¼.47) at 2
hours, and 0.1 (P¼.50) at discharge.
Table 2. Primary efficacy endpoints among patients receiving intravenous diphenhydramine or intravenous cetirizine for treatment of
acute urticaria.
Primary Efficacy Endpoint (Tested for Noninferiority)
IV Diphenhydramine 50 mg
(n[135)
IV Cetirizine 10 mg
(n[127) Difference (95% CI)
Patient-rated pruritus score at baseline
Mean (SD) 2.2 (0.7) 2.2 (0.7)
Patient-rated pruritis score at 2 h
Effect size 0.7 0.7
Mean (SD) 0.7 (0.9) 0.6 (0.9)
No. (%) of patients with 2-h LOCF* 78 (57.7) 78 (61.4)
Patient-rated pruritus score change from baseline at 2 h
Effect size –1.5 –1.7
Mean (SD) –1.5 (1.0) –1.6 (0.9) 0.1 (–0.1 to 0.3)†
LOCF, Last observation carried forward.
Intention-to-treat population, last observation carried forward.
*Last observation carried forward was used when a patient was discharged before the 2-hour assessment.
†Because the lower bound of the 95% CI for the treatment difference was greater than –0.5, effectiveness of intravenous cetirizine was demonstrated to be noninferior to that of
intravenous diphenhydramine.
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One serious adverse event of anaphylactic reaction in the
intravenous diphenhydramine group was reported in the
study. This event was moderate in severity and assessed by
the investigator as not related to study treatment. No
adverse events leading to study withdrawal and no deaths
occurred during the study.
LIMITATIONS
We acknowledge several limitations, including the
nature of the acute disease, which made a placebo-
controlled trial unfeasible. To our knowledge, there is no
history of a registration pivotal clinical trial for the
indication of acute urticaria. Therefore, the clinical
Table 4. Secondary efficacy endpoints among patients receiving intravenous diphenhydramine or intravenous cetirizine for treatment of
acute urticaria.
Endpoint
IV Diphenhydramine
50 mg (n[135)
IV Cetirizine
10 mg (n[127) P Value
Key secondary efficacy endpoints (tested for superiority)
Patients returning to any ED or clinic within 24 h of patient discharge, No. (%) 15 (11.1) 5 (3.9) .04*
Patients returning to any ED or clinic within 48 h of patient discharge, No. (%) 19 (14.1) 7 (5.5) .02*
Time spent at treatment center, h†
Effect size 1.9 2.0
Mean (SD) 2.1 (1.1) 1.7 (0.9) .005‡
Other secondary efficacy endpoints (tested for superiority)
Physician-rated extent of urticaria/erythema score reduction from baseline at 2 h
Effect size –0.8 –1.0
Mean (SD) –0.5 (0.6) –0.6 (0.6) .36§
Patients with pruritus treatment success, No. (%) 111 (82.2) 110 (86.6) .40*
Effectively treated patients,jj No. (%) 93 (68.9) 103 (81.1) .02*
Patients needing rescue medication, No. (%) 37 (27.4) 19 (15.0) .02*
Intention-to-treat population, last observation carried forward.
*Based on Fisher’s exact 2-sided test.
†Median was 2.0 h for intravenous diphenhydramine (n¼133) versus 1.4 h for intravenous cetirizine (n¼120).
‡Based on a generalized linear mixed-effects model 2-sided t test. The model consisted of time as the dependent variable and treatment as the fixed effect, baseline pruritus
score as a covariate, and site as a random effect.
§Based on a generalized linear mixed-effects model 2-sided t test. The model consisted of time as the dependent variable and site, treatment, and sitetreatment as fixed effects.
jjBased on physician’s assessment at readiness for discharge.
Table 3. Post hoc analysis of primary efficacy endpoints among elderly patients receiving intravenous diphenhydramine or intravenous
cetirizine for treatment of acute urticaria.
Primary Efficacy Endpoint IV Diphenhydramine 50 mg IV Cetirizine 10 mg Difference (95% CI); P Value
Patient-rated pruritus score change
from baseline at 2 h
<65 y
No. 126 118
Effect size –1.6 –1.7 0.1(–0.1 to 0.3);
Mean (SD) –1.5 (1.0) –1.6 (0.9) .55*
‡65 y
No. 9 9
Effect size –1.1 –2.0 0.9 (–0.2 to 2.0);
Mean (SD) –1.1 (1.1) –2.0 (1.0) .099*
Intention-to-treat population, last observation carried forward.
*Based on a generalized linear mixed-effects model 2-sided t test. The model consisted of the change from baseline at 2 hours as the dependent variable and treatment as the
fixed effect, baseline pruritus score as a covariate, and site as a random effect.
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measurements and rating scales used in this study were a
result of discussion with the Food and Drug
Administration. These may have some subjectivity;
however, the results from a pilot study16 using these
measurements and rating scales were similar. Anaphylactic
patients were excluded from the study when the
anaphylactic symptoms were still present; however, when
anaphylactic symptoms had been controlled, enrollment in
the study was allowed. In actual medical practice in EDs,
intravenous diphenhydramine (among other drugs) is
commonly used together with epinephrine, the first-line
therapy for anaphylaxis. The formulation of cetirizine
evaluated in this trial is currently for intravenous use only;
therefore, another limitation is that our results are not
applicable to clinical situations in which intramuscular
administration of antihistamines is preferred, either
institutionally or by individual practitioners. Finally,
although assessment of treatment effects based on specific
underlying cause(s) of urticaria was not a goal of this study,
it is possible that response to therapy depends on
underlying pathophysiology.
DISCUSSION
Early clinical development of intravenous cetirizine
revealed a pharmacokinetic profile that would be favorable
for an acute condition (ie, acute urticaria commonly
observed in EDs,14 urgent care centers, inpatient hospital
units, and oncology or other specialty or general medicine
clinics) requiring an immediate onset of action.17 Our
phase 3 results showed that although the effectiveness
(score reductions on pruritus and extent of urticaria/
erythema) of the treatments was comparable, intravenous
cetirizine was associated with fewer adverse events, less
sedation, shorter time in the treatment center, lower revisit
rate to the treatment center, and less rescue drug usage,
symptom recurrence, and additional medication usage.The
safety and tolerability of cetirizine have been well
established during the past 30 years,18 and clinical data
from this phase 3 study of intravenous cetirizine support a
safety profile similar to that of oral cetirizine. In the current
study, there were significantly fewer overall adverse events
reported in patients treated with intravenous cetirizine
compared with intravenous diphenhydramine. Dizziness
and nausea were the most common adverse events in the
study. Dizziness is a known adverse effect of
diphenhydramine,5 and all events of this type in this study
were reported only in patients treated with intravenous
diphenhydramine.
From a clinical practice standpoint, intravenous
diphenhydramine has been standard treatment for acute
urticaria when an intravenous treatment is required,5 either
used alone for moderate or mild cases or as an adjunct
therapy with other medications for severe cases such as
Figure 3. Patient-rated sedation score and change by visit. Intention-to-treat population. At 1 hour, the change in mean sedation
score was 0.7 (SD 0.9) for intravenous diphenhydramine versus 0.2 (SD 0.8) for intravenous cetirizine (P¼.003). At 2 hours, the
change in mean sedation score was 0.5 (SD 0.9) for intravenous diphenhydramine versus 0.1 (SD 0.8) for intravenous cetirizine
(P¼.03). At discharge, the change in mean sedation score was 0.5 (SD 0.9) for intravenous diphenhydramine versus 0.1 (SD 0.8)
for intravenous cetirizine (P¼.04).
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anaphylaxis. However, use of diphenhydramine has known
disadvantages in emergency medicine, in which crowding
and patient throughput represent important issues.19 Given
the sedating effects of diphenhydramine, discharging
patients from EDs after they receive the medication carries
potential risk to patient and public safety, leading some to
recommend that patients not drive a car for a period after
treatment.11,12 One study found that patients
compromised by a first-generation antihistamine were
unaware of their reduced ability to function, based on
impaired performance measures.9 This may place patients
in legal jeopardy because certain states have laws in place
that prohibit driving under the influence of any drug such
as diphenhydramine that impairs function.20 Additionally,
because of its anticholinergic and sedation adverse effects,
use of diphenhydramine is discouraged in the 2019
American Geriatrics Society Beers Criteria for potentially
inappropriate medication use in older adults, with
recognition that acute use for severe allergic reactions may
be appropriate because there are no alternatives.21 In a
2000 to 2006 National Hospital Ambulatory Medical Care
Survey study involving elderly patients (65 years) and
using previous yet similar Beers criteria, diphenhydramine
accounted for 1.17% of ED visits in the cohort.22 In our
study, 9 patients per arm were aged 65 years or older
(representing 7% of the study population), with no
significant difference in the primary outcome between the
study treatments in this small cohort of elderly patients. In
addition, no overall differences in sedation and overall
safety were observed between patients aged 65 years or
older versus younger patients. Overall, these clinical trial
data have applicability for emergency medicine as well as
other settings, including emerging models of care in which
safety and sedation will be of paramount importance.
Table 5. Summary of adverse events by system organ class and preferred term.
Adverse events IV Diphenhydramine 50 mg (n[135) IV Cetirizine 10 mg (n[127)
Patients with 1 adverse event, No. (%) 18 (13.3) 5 (3.9)
Nervous system disorders, No. (%) 10 (7.4) 3 (2.4)
Dizziness 6 (4.4) 0
Burning sensation 2 (1.5) 0
Dysgeusia 1 (0.7) 1 (0.8)
Headache 1 (0.7) 1 (0.8)
Paresthesia 0 1 (0.8)
Presyncope 0 1 (0.8)
Gastrointestinal disorders, No. (%) 4 (3.0) 1 (0.8)
Nausea 4 (3.0) 0
Dyspepsia 0 1 (0.8)
Vomiting 1 (0.7) 0
General disorders and administration site conditions, No. (%) 3 (2.2) 1 (0.8)
Pyrexia 2 (1.5) 0
Warm sensation 0 1 (0.8)
Injection site pain 1 (0.7) 0
Skin and subcutaneous tissue disorders, No. (%) 3 (2.2) 1 (0.8)
Urticaria 2 (1.5) 0
Erythema 1 (0.7) 0
Hyperhidrosis 0 1 (0.8)
Pruritus 1 (0.7) 0
Cardiac disorders, No. (%) 1 (0.7) 0
Bradycardia 1 (0.7) 0
Immune system disorders, No. (%) 1 (0.7) 0
Anaphylactic reaction 1 (0.7) 0
Safety population.
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Although economic outcomes were not captured in the
current clinical trial, the observed reductions of time spent
in ED, ED readmission rate, and rescue medication use
with intravenous cetirizine may confer cost savings.
Because the use of first-generation oral antihistamines
has markedly decreased with the availability of second-
generation agents owing to both efficacy and safety
considerations across many conditions that include chronic
urticaria and allergic rhinitis, the introduction of
intravenous cetirizine may allow similar advancement in
the treatment of acute urticaria throughout the health care
system.
In conclusion, this study demonstrated that intravenous
cetirizine (10 mg) is as effective as intravenous
diphenhydramine (50 mg) in the treatment of acute
urticaria while offering benefits that include less sedation
and a lower overall adverse event rate, as well as less time
spent at the treatment center and a lower rate of return to
the facility.
The authors acknowledge Laurie Orloski, PharmD, and
LoAn K. Ho, PharmD, both of whom are consultants for
Forward WE Go, a division of Wesley Enterprise, Inc., and
provided medical writing and editorial support; and the study
investigators, their research teams, and the study patients.
Supervising editor: Donald M. Yealy, MD. Specific detailed
information about possible conflict of interest for individual editors
is available at https://www.annemergmed.com/editors.
Author affiliations: From the Center for Resuscitation Science,
Department of Emergency Medicine, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA (Abella);
Allergy and Asthma Associates of Southern California, Mission
Viejo, CA (Berger); the Department of Pediatrics, Medical College of
Georgia at Augusta University, Augusta, GA (Blaiss); the
Department of Emergency Medicine, University of Ottawa and
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
(Stiell); the Department of Emergency Medicine, Einstein
Healthcare Network, Philadelphia, PA (Herres); the Department of
Emergency Medicine, University of Cincinnati, Cincinnati, OH
(Moellman); the Department of Emergency Medicine, The Warren
Alpert Medical School of Brown University and Rhode Island
Hospital, Providence, RI (Suner); the Department of Emergency
Medicine, University of Alabama, Birmingham, AL (Kessler); the
Department of Emergency Medicine, Henry Ford Health System,
Detroit, MI (Klausner); the Department of Emergency Medicine,
The Ohio State University Wexner Medical Center, Columbus, OH
(Caterino); and TerSera Therapeutics, Deerfield, IL (Du).
Author contributions: JD conceived the study and designed the
trial. IGS, JPH, JJM, SS, AK, HAK, and JMC undertook recruitment
at participating centers, supervised patient enrollment, supervised
conduct of the trial at their respective centers, and supervised
data collection, including quality control. BSA, MSB, HAK, and JD
collaborated on the outline and the initial 2 drafts of the article,
and all authors contributed substantially to its subsequent revision
and approval. BSA takes responsibility for the paper as a whole.
All authors attest to meeting the four ICMJE.org authorship criteria:
(1) Substantial contributions to the conception or design of the
work; or the acquisition, analysis, or interpretation of data for the
work; AND (2) Drafting the work or revising it critically for important
intellectual content; AND (3) Final approval of the version to be
published; AND (4) Agreement to be accountable for all aspects of
the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and
resolved.
Funding and support: By Annals policy, all authors are required to
disclose any and all commercial, financial, and other relationships
in any way related to the subject of this article as per ICMJE conflict
of interest guidelines (see www.icmje.org). Funding for this
research was provided by JDP Therapeutics and TerSera
Therapeutics. Drs. Abella, Berger, and Blaiss report receiving
consulting fees from TerSera Therapeutics and JDP Therapeutics.
Dr. Du reports receiving consulting fees from TerSera Therapeutics.
JDP Therapeutics provided statistical expertise on study design.
Publication dates: Received for publication December 21, 2019.
Revisions received April 22, 2020, and May 12, 2020. Accepted
for publication May 18, 2020.
Presented at the American College of Allergy, Asthma, and
Immunology meeting, November 2018, Seattle, WA; and the
American College of Emergency Physicians Research Forum,
October 2019, Denver CO.
Trial registration number: NCT02935699
REFERENCES
1. Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am
Fam Physician. 2017;95:717-724.
2. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, et al. Urticaria and
angioedema: an update on classification and pathogenesis. Clin Rev
Allergy Immunol. 2018;54:88-101.
3. Centers for Disease Control and Prevention. National Hospital Ambulatory
Medical Care Survey. 2016 emergency department summary. Available
at: https://www.cdc.gov/nchs/data/nhamcs/web_tables/2016_ed_
web_tables.pdf. Accessed July 13, 2019.
4. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and
management of acute and chronic urticaria: 2014 update. J Allergy
Clin Immunol. 2014;133:1270-1277.
5. Benadryl (diphenhydramine hydrochloride injection, USP) [package
insert] New Brunswick, NJ: Johnson & Johnson; 2016.
6. Banerji A, Long AA, Camargo CA Jr. Diphenhydramine versus
nonsedating antihistamines for acute allergic reactions: a literature
review. Allergy Asthma Proc. 2007;28:418-426.
7. Gengo F, Gabos C, Miller JK. The pharmacodynamics of
diphenhydramine-induced drowsiness and changes in mental
performance. Clin Pharmacol Ther. 1989;45:15-21.
8. Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state
effects of diphenhydramine and loratadine on sedation, cognition,
mood, and psychomotor performance. Arch Intern Med.
1997;157:2350-2356.
9. Kay GG. The effects of antihistamines on cognition and performance.
J Allergy Clin Immunol. 2000;105(6 pt 2):S622-S627.
10. American Regent, Inc. Hydroxyzine hydrochloride injection, USP.
Prescribing information. Available at: https://www.americanregent.
Abella et al Intravenous Cetirizine Versus Intravenous Diphenhydramine for Urticaria
Volume -, no. - : - 2020 Annals of Emergency Medicine 11
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 17, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
com/media/2501/hydroxyzine-prescribing-information.pdf. Accessed
March 27, 2020.
11. Inami A, Matsuda R, Grobosch T, et al. A simulated car-driving study on
the effects of acute administration of levocetirizine, fexofenadine, and
diphenhydramine in healthy Japanese volunteers. Hum
Psychopharmacol. 2016;31:167-177.
12. Verster JC, Volkerts ER. Antihistamines and driving ability: evidence
from on-the-road driving studies during normal traffic. Ann Allergy
Asthma Immunol. 2004;92:294-303.
13. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine,
diphenhydramine, and alcohol on driving performance. A randomized,
placebo-controlled trial in the Iowa driving simulator. Ann Intern Med.
2000;132:354-363.
14. Park JH, Godbold JH, Chung D, et al. Comparison of
cetirizine and diphenhydramine in the treatment of acute
food-induced allergic reactions. J Allergy Clin Immunol.
2011;128:1127-1128.
15. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO
guideline for the definition, classification, diagnosis and management
of urticaria. Allergy. 2018;73:1393-1414.
16. Quzyttir. Prescribing information. Available at: https://documents.
tersera.com/quzyttir/QuzyttirPrescribingInformation.pdf. Accessed
March 27, 2020.
17. Francis M, Noumeir M, Sicard E, et al. A phase I assessment of the
safety and tolerability profile of novel treatments for acute allergic
reactions administered by intravenous and intramuscular injection
formulations. J Allergy Clin Immunol. 2013;131(2 suppl):AB26.
18. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic
disorders. Drugs. 2004;64:523-561.
19. McKenna P, Heslin SM, Viccellio P, et al. Emergency department and
hospital crowding: causes, consequences, and cures. Clin Exp Emerg
Med. 2019;6:189-195.
20. Moskowitz H, Jeavons Wilkinson C. Antihistamines and Driving-
Related Behavior: A Review of the Evidence for Impairment. US Dept
of Transportation; 2004. Report DOT HS 809 714. Available at:
https://one.nhtsa.gov/people/injury/research/antihistamines/
Antihistamines%20Web/pages/1%20Introduction.htm. Accessed
July 30, 2019.
21. American Geriatrics Society Beers Criteria® Update Expert Panel.
American Geriatrics Society 2019 updated AGS Beers Criteria® for
potentially inappropriate medication use in older adults. J Am Geriatr
Soc. 2019;67:674-694.
22. Meurer WJ, Potti TA, Kerber KA, et al. Potentially inappropriate
medication utilization in the emergency department visits by older
adults: analysis from a nationally representative sample. Acad Emerg
Med. 2010;17:231-237.
Intravenous Cetirizine Versus Intravenous Diphenhydramine for Urticaria Abella et al
12 Annals of Emergency Medicine Volume -, no. - : - 2020
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 17, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
